Dew, Did that not answer this persons question on the CC:
Enanta initiated with an Underperform at Evercore
Evercore ISI analyst Liisa Bayko initiated coverage of Enanta with an Underperform rating and $30 price target.
jbog Member Level Friday, 05/01/20 09:49:12 AM Re: DewDiligence post# 231770 0 Post # 231771 of 235831 I'll have to dig up my notes but this may be enough of a drop to bring Enata close to zero income with their current burn. If so Enta will be back in the $30's until it shows some progress
ENTA’s royalty rate from ABBV is tiered, as shown in the table in #msg-142808661. The royalty rate is applied to the 50% Glecaprevir component of Mavyret, a 2-drug combination. During calendar 4Q20 (ENTA’s FY1Q21), ABBV sold $481M of Mavyret. (ABBV issued full-year 2021 guidance for Mavyret sales of $2.0B.)
ENTA’s 12/31/20 cash balance of $405M was down $14M from 9/30/20 (#msg-159678084).
ENTA previously issued FY2021* guidance for gross operating expenses (including non-cash components): $145-165M for R&D; and $27-33M for G&A. FY1Q21 actual operating expenses ($36.7M for R&D; $7.4M for G&A) were inline with the prior guidance.